Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC). A phase II trial of ...
JCO Precision Oncology Conversations podcasts feature discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations ...
A newly identified vulnerability of small cell neuroendocrine carcinoma could represent a potential treatment strategy for these aggressive and difficult-to-treat cancers. University of California, ...
UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...
UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results